Strain Name | NOG-hGM-CSF/hIL-3 Tg (NOG-EXL) |
---|
NOG-EXL mouse was established the following method. Vectors containing human IL-3 or GM-CSF genes downstream of the SRa promoter were microinjected into C57BL/6J-scid mouse embryos and the resulting transgenic mouse was backcrossed to NOG mouse.
The followings are added to the features of the NOG mouse.
We will introduce the development history of NOG-EXL mouse, the characteristics of NOG-EXL mouse engrafted with HSCs (humanized mouse), and their main research applications.
Establishment of a human allergy model using human IL-3/GM-CSF-transgenic NOG mice. (human allergy, NOG-EXL)
J Immunol. 2013 Sep 15;191(6):2890-9. doi: 10.4049/jimmunol.1203543. Epub 2013 Aug 16.
Ryoji Ito, Takeshi Takahashi, Ikumi Katano, Kenji Kawai, Tsutomu Kamisako, Tomoyuki Ogura, Miyuki Ida-Tanaka, Hiroshi Suemizu, Satoshi Nunomura, Chisei Ra, Akio Mori, Sadakazu Aiso, Mamoru ItoCo-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML. (AML, NOG-EXL)
In Vivo. 2022 Jul-Aug;36(4):1615-1627. doi: 10.21873/invivo.12872.
Daniel H Albert, Neal C Goodwin, Angela M Davies, Jenny Rowe, Gerold Feuer, Michael Boyiadzis, Kathleen A Dorritie, Maria Mancini, Regina Gandour-Edwards, Brian A Jonas, Gautam Borthakur, Ibrahim Aldoss, David A Rizzieri, Olatoyosi Odenike, Thomas Prebet, Sanjana Singh, Relja Popovic, Y U Shen, Keith F McDaniel, Warren M Kati, Dimple A Modi, Monica Motwani, Johannes E Wolff, David J FrostEliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors.(CML-LSCs, NOG-EXL)
Nature Communications volume 13, Article number: 271 (2022)
Yosuke Tanaka, Reina Takeda, Tsuyoshi Fukushima, Keiko Mikami, Shun Tsuchiya, Moe Tamura, Keito Adachi, Terumasa Umemoto, Shuhei Asada, Naoki Watanabe, Soji Morishita, Misa Imai, Masayoshi Nagata, Marito Araki, Hitoshi Takizawa, Tomofusa Fukuyama, Chrystelle Lamagna, Esteban S. Masuda, Ryoji Ito, Susumu Goyama, Norio Komatsu, Tomoiku Takaku & Toshio KitamuraTransplantation of insulin-producing cells derived from human mesenchymal stromal/stem cells into diabetic humanized mice. (hAT-MSCs, NOG-EXL)
Stem Cell Res Ther. 2022 Jul 26;13(1):350. doi: 10.1186/s13287-022-03048-y.
Ghoneim MA, Gabr MM, Refaie AF, El-Halawani SM, Al-Issawi MM, Elbassiouny BL, Kader MAAE, Ismail AM, Zidan MF, Karras MS, Magar RW, Khater SM, Ashamallah SA, Zakaria MM, Kloc M.Bovine β-lactoglobulin-induced passive systemic anaphylaxis model using humanized NOG hIL-3/hGM-CSF transgenic mice. (passive systemic anaphylaxis model, NOG-EXL )
Int Immunol. 2021 Mar 1;33(3):183-189. doi: 10.1093/intimm/dxaa067.
Ito R, Katano I, Otsuka I, Takahashi T, Suemizu H, Ito M, Simons PJ.The Tumor Milieu Promotes Functional Human Tumor-Resident Plasmacytoid Dendritic Cells in Humanized Mouse Models. (pDC, humanized mice, NOG-EXL)
Front Immunol. 2020 Sep 8;11:2082. doi:10.3389/fimmu.2020.02082. eCollection 2020.
Maser IP, Hoves S, Bayer C, Heidkamp G, Nimmerjahn F, Eckmann J, Ries CH.Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents. (humanized mice, NOG-EXL, Immune oncology, PDX)
Curr Protoc Pharmacol. 2020 Jun;89(1):e77. doi: 10.1002/cpph.77.
Ghoneim MA, Gabr MM, Refaie AF, El-Halawani SM, Al-Issawi MM, Elbassiouny BL, Kader MAAE, Ismail AM, Zidan MF, Karras MS, Magar RW, Khater SM, Ashamallah SA, Zakaria MM, Kloc M.HIV Replication in Humanized IL-3/GM-CSF-Transgenic NOG Mice. (humanized mice, NOG-EXL, HIV)
Pathogens. 2019 Mar 12;8(1):33. doi: 10.3390/pathogens8010033.
Perdomo-Celis F, Medina-Moreno S, Davis H, Bryant J, Zapata JC.BLT-Immune Humanized Mice as a Model for Nivolumab-Induced Immune-Mediated Adverse Events: Comparison of the NOG and NOG-EXL Strains. (NOG, NOG-EXL)
Toxicol Sci. 2019 May 1;169(1):194-208. doi: 10.1093/toxsci/kfz045.
Weaver JL, Zadrozny LM, Gabrielson K, Semple KM, Shea KI, Howard KE.